Answers are grounded in this paper and cite their sources.
Background. Chimeric antigen receptor T-cell (CAR-T) therapy has changed the prognosis of patients with relapsed or refractory hematological malignancies but is among the most expensive oncology technologies: US list prices in 2025 were USD 462,000–594,000. Since April 2026, CAR-T therapy has been included in the Russian State Guarantees Programme, which makes the analysis of international economic evidence relevant. Objective: to systematize international experience in the economic evaluation of CAR-T therapy for hematological malignancies, to assess the comparability of its results, and to identify implications for the healthcare system of the Russian Federation. Material and methods. A narrative review of PubMed/MEDLINE, Scopus, Cochrane Library, eLibrary and CyberLeninka (January 2017 – June 2026) and of documents of regulatory and health technology assessment agencies was performed. For economic evaluations, country and perspective, comparator, willingness-to-pay threshold and results were compared; the Russian tariff was compared with international cost data converted at the official Bank of Russia exchange rate. A total of 50 sources were included. Results. In 47 economic evaluations, the incremental cost-effectiveness ratio (ICER) of CAR-T therapy ranged from USD 9,424 to 4,124,105 per quality-adjusted life year (QALY) in adults and from USD 20,784 to 243,177/QALY in children. The comparability of studies is limited by differences in comparators, survival extrapolation, discount rates, currencies and willingness-to-pay thresholds (from USD 37,700/QALY in China to USD 150,000/QALY in the USA). For the same indication (second-line axicabtagene ciloleucel in diffuse large B-cell lymphoma), US ICERs ranged from USD 66,381 to 142,327/QALY. A regression analysis of 45 studies found no association of cost-effectiveness with product, line of therapy or country. The Russian compulsory health insurance tariff of 7.03 million rubles (USD 88,200 at the Bank of Russia rate of April 6, 2026) is comparable with episode costs excluding the product in the UK (6.64 million rubles) and Italy (6.82 million rubles). Conclusion. Results of foreign economic evaluations of CAR-T therapy cannot be transferred to Russia without adaptation. Evidence-based reimbursement requires a national outcomes registry, data on actual costs of Russian centers with regular tariff revision, and methodological guidance for the evaluation of single-administration therapies.
No takes yet. Share an insight, caveat, or question.
Gilev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: